EEM is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis
It could be medically necessary
It is additionally approved to reduce the risk of kidney disease progression, kidney failure, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease
The FDA's iPLEDGE program overview details each stakeholder's obligations
Methods From a comprehensive literature review of existing well-being scales, item contents were identified, and 21 questions were distilled and standardized in language and tone
The co-administration of cagrilintide and semaglutide leverages their complementary mechanisms for enhanced weight management and glycemic control, promoting significant reductions in bodyweight and improvements in metabolic health in populations with overweight, obesity, and type 2 diabetes 1-3